Study of the contributory factors to metabolic abnormalities in resistant schizophrenia - 13/04/16
Résumé |
Introduction |
Schizophrenia is a developmental disorder that includes non-psychiatric abnormalities [2]. Metabolic abnormalities prior to antipsychotic treatment exist. The clozapine metabolic profile causes clozapine underuse in resistant schizophrenia [1].
Objectives |
To correlate metabolic profile with psychiatric severity and compare the correlations between clozapine/non-clozapine patients.
Aims |
To determine possible contributory factors to metabolic abnormalities in schizophrenia.
Methods |
We cross-sectionally analyzed all patients from a Spanish long-term mental care facility (n=139). Schizophrenic/schizoaffective patients were selected (n=118). N=31 used clozapine. We paired clozapine and non-clozapine patients by sex and age and assessed metabolic and psychopathologic variables.
We compared psychopathologic variables between patients with/without cardiometabolic treatment and the differences between clozapine/non-clozapine groups.
Results |
We analyzed: 27 clozapine/29 non-clozapine patients. A total of 67,9% males with a mean age of 51.3 (SD 9.6) years. In the whole sample TG negatively correlated with Negative-CGI (r: −0,470, P: 0.049) and HDL-cholesterol correlates with Global-CGI(r: 0,505, P: 0.046). Prolactin correlated with the number of antipsychotics (r: 0.581, P: 0.023) and IMC (r: 0.575, P: 0.025). Clozapine group took less antipsychotics [Fisher (P: 0.045)] and had higher scores in total BRPS scale [t-Student (P: 0.036)]. They did not use more cardiometabolic treatment. There were no psychopathological differences between cardiometabolic treated/non-treated patients. In the non-cardiometabolic treated group (n=35/62,5%), IMC negatively correlated with positive and total BPRS, positive, cognitive and global-CGI. We found negative correlations between metabolic parameters and psychopathology in clozapine (40%) and non-clozapine subgroups (60%). In the cardiometabolic treated group (n=21/37,5%), we did not find these correlations in either of clozapine (61.9%) or non-clozapine (38.1%) subgroups.
Conclusions |
Severity [2], prolactine [3] and treatment [1] could play a role in metabolic parameters. In our sample we found negative correlations between psychopathological and metabolic parameters.
References not available.
Le texte complet de cet article est disponible en PDF.Plan
Vol 33 - N° S
P. S584 - mars 2016 Retour au numéro
Article précédent
- Catatonic schizophrenia vs anti-NMDA receptor encephalitis – A video case report
- A. Ponte, J. Gama Marques, L. Carvalhão Gil, C. Nobrega, S. Pinheiro, A. Brito
- Awareness of illness and psychosis
- R. Remesal Cobreros, R. Alonso Díaz, E. Cortázar Alonso, M. Andrés Villa
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?